The Evaluation of Pazopanib Treatment Experience and Real-Life Data in Metastatic Soft Tissue Sarcoma
Merve Keskinkilic1, Deniz Bakircioglu2, Huseyin Salih Semiz3, Tugba Yavuzsen3, Ilhan Oztop31Department of Medical Oncology, Dokuz Eylul University Faculty of Medicine, Izmir, Türkiye, 2Department of Internal Medicine, Dokuz Eylul University Faculty of Medicine, Izmir, Türkiye, 3Department of Medical Oncology, Dokuz Eylul University, Institute of Oncology, Izmir, Türkiye
Objectives: We aimed to share real-life data of pazopanib in non-liposarcoma STS patients in soft tissue sarcoma (STS), which is rare among adult cancers. Methods: Characteristics of adult patients treated with pazopanib for metastatic STS were recorded retrospectively. Response rate, survival and toxicity data related to pazopanib treatment were evaluated in SPSS program with appropriate statistical analysis. Results: The median age of 50 patients in our study was 48.4 (17.1- 92.4) years. The most common histological subtype was leomyosarcoma (11 patients, 22.0%), and the most common primary tumor location was the intra-abdominal region (17 patients, 34.0%). The most common site of metastasis was the lung (35 patients, 70.0%). Forty three of the patients had received two or more lines while twenty-seven of the patients had received three or more line treatments. With pazopanib treatment, the overall response rate (ORR): 12%, median progression-free survival (mPFS): 5.8 months, and median overall survival (mOS): 8.6 months. Grade 3/4 toxicity was observed in a total of 5 (10.0%) patients in the entire group.The most common toxicity was fatigue (15 patients, 30.0%). Conclusion: In our study, pazopanib treatment provided a PFS contribution similar to the literature and showed a tolerable toxicity profile in patients diagnosed with liposarcoma and non-GIST soft tissue sarcoma that progressed after anthracycline-based treatment. Keywords: Soft tissue sarcoma, pazopanib, treatment
Cite This Article
Keskinkilic M, Bakircioglu D, Semiz H, Yavuzsen T, Oztop I. The Evaluation of Pazopanib Treatment Experience and Real-Life Data in Metastatic Soft Tissue Sarcoma. EJMI. 2023; 7(4): 407-413
Corresponding Author: Merve Keskinkilic